- Home
- WSBF vs TVRD Comparison
WSBF vs TVRD Comparison
Compare WSBF & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WSBF
- TVRD
- Stock Information
- Founded
- WSBF 1921
- TVRD 2017
- Country
- WSBF United States
- TVRD United States
- Employees
- WSBF N/A
- TVRD N/A
- Industry
- WSBF Savings Institutions
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- WSBF Finance
- TVRD Health Care
- Exchange
- WSBF Nasdaq
- TVRD Nasdaq
- Market Cap
- WSBF 240.7M
- TVRD 246.5M
- IPO Year
- WSBF N/A
- TVRD N/A
- Fundamental
- Price
- WSBF $12.92
- TVRD $28.34
- Analyst Decision
- WSBF
- TVRD Strong Buy
- Analyst Count
- WSBF 0
- TVRD 2
- Target Price
- WSBF N/A
- TVRD $52.00
- AVG Volume (30 Days)
- WSBF 49.7K
- TVRD 48.4K
- Earning Date
- WSBF 07-24-2025
- TVRD 05-13-2025
- Dividend Yield
- WSBF 4.63%
- TVRD N/A
- EPS Growth
- WSBF 95.86
- TVRD N/A
- EPS
- WSBF 1.02
- TVRD N/A
- Revenue
- WSBF $133,551,000.00
- TVRD N/A
- Revenue This Year
- WSBF N/A
- TVRD N/A
- Revenue Next Year
- WSBF N/A
- TVRD N/A
- P/E Ratio
- WSBF $12.70
- TVRD N/A
- Revenue Growth
- WSBF 1.81
- TVRD N/A
- 52 Week Low
- WSBF $11.61
- TVRD $8.13
- 52 Week High
- WSBF $16.86
- TVRD $34.31
- Technical
- Relative Strength Index (RSI)
- WSBF 56.87
- TVRD N/A
- Support Level
- WSBF $12.49
- TVRD N/A
- Resistance Level
- WSBF $12.90
- TVRD N/A
- Average True Range (ATR)
- WSBF 0.26
- TVRD 0.00
- MACD
- WSBF 0.04
- TVRD 0.00
- Stochastic Oscillator
- WSBF 63.53
- TVRD 0.00
About WSBF Waterstone Financial Inc. (MD)
Waterstone Financial Inc is a holding company. Through its subsidiaries, it operates in two reportable segments: Community Banking and Mortgage Banking. The Community Banking segment provides consumer and business banking products and services to customers, which include various types of loans, deposits, and personal investment services. The Mortgage Banking segment involves residential mortgage loans for the primary purpose of sale in the secondary market. The vast majority of its revenue comes from the Community Banking segment.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.